Boston Scientific (NYSE:BSX) Given New $96.00 Price Target at Evercore ISI

Boston Scientific (NYSE:BSX) had its price target cut by equities research analysts at Evercore ISI from $112.00 to $96.00 in a report released on Thursday, Marketbeat Ratings reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Evercore ISI’s target price points to a potential upside of 23.65% from the company’s previous close.

BSX has been the subject of several other research reports. Oppenheimer dropped their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. Barclays dropped their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research report on Tuesday. Morgan Stanley dropped their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday. Canaccord Genuity Group set a $112.00 price objective on Boston Scientific in a report on Thursday. Finally, UBS Group dropped their price objective on Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $111.40.

Boston Scientific Trading Up 2.8%

Shares of NYSE:BSX traded up $2.14 during midday trading on Thursday, reaching $77.64. 10,129,601 shares of the company’s stock were exchanged, compared to its average volume of 15,355,010. The firm’s 50 day simple moving average is $94.37 and its two-hundred day simple moving average is $99.13. The stock has a market cap of $115.09 billion, a price-to-earnings ratio of 41.56, a P/E/G ratio of 1.63 and a beta of 0.67. Boston Scientific has a fifty-two week low of $74.86 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter last year, the firm earned $0.70 EPS. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.50% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently modified their holdings of the stock. Steph & Co. purchased a new stake in Boston Scientific in the third quarter worth $25,000. Financial Consulate Inc. bought a new stake in Boston Scientific during the 3rd quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp lifted its stake in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the second quarter worth about $26,000. Finally, United Community Bank grew its holdings in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beats on top and bottom lines: BSX reported $0.80 EPS vs. $0.78 consensus and $5.29B in sales (up ~16% YoY), with margin improvement and organic growth — a reminder the business still has solid underlying momentum. Press Release
• Positive Sentiment: Major Wall Street firms maintain constructive ratings and still see multi‑month upside despite cuts — several firms kept Buy/Overweight or Outperform stances with price targets well above current levels (examples: Morgan Stanley, Mizuho, Robert W. Baird). This provides analyst support for any longer‑term recovery. Analyst Notes
• Neutral Sentiment: Guidance was mixed/tepid: FY26 EPS guide of $3.43–3.49 and revenue $22.2–22.4B landed around or slightly under consensus (consensus EPS ~3.46; revenue at the low end), and Q1 EPS/revenue guidance was steady but conservative — this is watchlist data rather than a surprise miss. Company Slide Deck
• Negative Sentiment: Market reaction focuses on soft 2026 outlook and a key division miss: Electrophysiology sales were lighter than investors hoped, which, combined with conservative growth assumptions, drove steep selling pressure. Reuters: Guidance Reaction
• Negative Sentiment: Analysts cut price targets after the print: multiple firms trimmed PTs (examples: Morgan Stanley $130→$118; Needham $121→$97; Mizuho $140→$115; Truist $120→$95; Robert W. Baird $118→$101), amplifying the downside pressure. Benzinga: PT Cuts
• Negative Sentiment: Flow and insider activity added selling bias: unusual put buying ahead of/after the print and a large insider sale by CEO Michael Mahoney (160,901 shares) contributed to negative sentiment and volatility. SEC Filing

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.